Document is current
Any future updates will be listed below
-
Authors
Parravano, Mariacristina https://orcid.org/0000-0002-2223-7311
Ferro Desideri, Lorenzo
Costanzo, Eliana https://orcid.org/0000-0002-9916-8895
Eldridge, Nina
Zinkernagel, Martin
Anguita, Rodrigo
Sacconi, Riccardo
Querques, Giuseppe
- License Information
-
More Information
Article History
Received: 12 December 2025
Accepted: 9 April 2026
First Online: 6 May 2026
Declarations
:
: Mariacristina Parravano reported personal fee from Novartis, Bayer, Roche, Abbvie outside the submitted work. Giuseppe Querques is Consultant/Advisor for: 4DMT, Abbvie, Apellis, Bayer, EyePoint, iCARE-CenterVue, Heidelberg Engineering, Novartis, Roche, Sandoz, Zeiss; Consultant for: Baush &Lomb, Thea; Advisor for: Boehringer Ingelheim, Lumithera outside the submitted work. Riccardo Sacconi is Consultant for: AbbVie, Bayer Shering-Pharma, Boehringer Ingelheim, Carl Zeiss Meditec, Hoffmann-La-Roche, Novartis outside the submitted work. Lorenzo Ferro Desideri, Eliana Costanzo, Nina Eldridge, Martin Zinkernagel, have nothing to disclose. Rodrigo Anguita and Giuseppe Querques are editorial board members of Ophthalmology and Therapy. Rodrigo Anguita and Giuseppe Querques were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: The research was conducted following the ethical principles of the Declaration of Helsinki, and institutional review board approval was obtained by the Cantonal Ethics Committee Bern (BASEC-ID-2023-00768). Informed consent was acquired from all participants before data collection.
